Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120778 | 1.00 | CYP3A4 (0.36) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL19791889 | 0.98 | CYP3A4 (0.35) | CYP3A4TRPA1ALDH1A1HPGDTDP1 | |
| SCHEMBL22012689 | 0.79 | PARP1 (0.32) | CYP3A4TRPA1 | |
| SCHEMBL19791887 | 0.78 | TRPA1 (0.30) | CYP3A4TRPA1 | |
| SCHEMBL6867779 | 0.78 | TRPA1 (0.33) | CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL11103476 | 0.77 | CYP3A4 (0.46) | CYP3A4TRPA1TDP1 | |
| SCHEMBL19791775 | 0.77 | TRPA1 (0.32) | CYP3A4TRPA1 | |
| SCHEMBL19791962 | 0.76 | TRPA1 (0.32) | CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL20681025 | 0.76 | TRPA1 (0.32) | CYP3A4TRPA1ALDH1A1 | |
| SCHEMBL9709998 | 0.71 | CYP3A4 (0.37) | CYP3A4TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2020254697-A1 | FUSED 1,2 THIAZOLES AND 1,2 THIAZINES WHICH ACT AS NL3P3 MODULATORS | AC IMMUNE SA (CH) | 2020-12-24 | — | — | WO | disclosed |
| WO-2018015445-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | NodThera Limited (GB) | 2018-01-25 | — | — | WO | disclosed |
| EP-3272739-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | NodThera Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
| EP-3272739-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | NodThera Limited (GB) | 2018-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011652-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CYP3A4 2521/4885TRPA1 148/4885ALDH1A1 2065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.